Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511089 | 0.87 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2HSD17B10GAA | |
| SCHEMBL2669096 | 0.85 | KMT2A (0.43) | ALDH1A1KDM4ESMN1; SMN2HSD17B10NPSR1 | |
| SCHEMBL13652939 | 0.82 | HSD17B10 (0.42) | ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD | |
| SCHEMBL971465 | 0.79 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2HSD17B10GAA | |
| SCHEMBL12200548 | 0.76 | MAPT (0.38) | ALDH1A1KDM4ESMN1; SMN2HSD17B10GAA | |
| SCHEMBL12636201 | 0.74 | ACACB (0.33) | ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPT | |
| SCHEMBL25280744 | 0.74 | KDM4E (0.52) | ALDH1A1KDM4ESMN1; SMN2HSD17B10GAA | |
| SCHEMBL6601697 | 0.73 | ALDH1A1 (0.70) | ALDH1A1KDM4ESMN1; SMN2HSD17B10GAA | |
| SCHEMBL2669105 | 0.73 | PIK3CD (0.43) | ALDH1A1KDM4ESMN1; SMN2NPSR1HPGD | |
| SCHEMBL10049899 | 0.71 | PDE10A (0.44) | ALDH1A1KDM4ESMN1; SMN2HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | ALDH1A1 606/4885KDM4E 2516/4885SMN1; SMN2 3312/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | ALDH1A1 606/4885KDM4E 2516/4885SMN1; SMN2 3312/4885 |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | ALDH1A1 2196/4885KDM4E 3701/4885SMN1; SMN2 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.